SenzaGen talks about start-ups and entrepreneurship in meeting with Swedish Parliament in Stockholm - and local visit at Medicon Village

As of nine years/each year, the Swedish business organisation ALMI Skåne hosts a much appreciated and well-attended meeting between members of parliament and entrepreneurs from the start-up scene in Skåne and Blekinge. The ninth edition of the meeting took place on 19 of April, at the parliament in Stockholm.

The aim of the meeting is to highlight the positive diversity within the business scene in Skåne, Sweden, and to shed some light on the reality in which these companies live and breath. This year, three local companies attended the meeting where they were able to present and discuss their companies prospects’, opportunities and challenges. The personal setting of the meeting was appreciated by both MPs and entrepreneurs.

SenzaGen was one of the three attending companies, represented by the CEO Anki Malmborg Hager who took the opportunity to present SenzaGen and her experiences and thoughts about entrepreneurship. The presentation covered the journey that SenzaGen has taken since the start in 2010 as well as the situation of other companies originating from Lund University.

- I think the meeting was very fruitful. The representatives of the Committee on Industry and Trade and the Committee on Education were very familiar with and committed to the issues that are most important to us as a spin out from Lund University University. For that reason, it is especially exciting that they will visit us at Medicon Village in May, says Anki Malmborg Hager, CEO of SenzaGen AB.

The Committee on Education and the Committee on Industry and Trade will visit Medicon Village and SenzaGen at two separate occasions during May.


About Us

About SenzaGen SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit About GARD GARD is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have up to 90% reliability. This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75%. SenzaGen's tests are also capable of measuring the potency of a substance's allergenic properties. Consequently GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.